Is There Still a Problem With Vaccines?

3min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

Efforts to create locally made vaccines have failed in the past. Companies can knock smaller companies out of the market by dropping their prices, because they can afford to do so. And then when you're a government or we can also talk about groups that purchase for countries that don't have a large d d p. The whole point of this whole project is to have sustainable manufacturing, not just one company that makes copet vaccines and then goes away.

Inequity has been a central feature of the COVID19 pandemic. From health outcomes to access to vaccines, COVID has pushed long-standing disparities out of the shadows and into the public eye and many of these problems are global. In this episode of Coronapod we dig into a radical new collaboration of 15 countries - co-led by the WHO, and modelled on open-science. The project, called the mRNA vaccine technology transfer hub, aims to create independent vaccine hubs that could supply the global south, and take on the giants of the pharmaceutical industry in the process. But the road ahead is long - the challenges are complex and numerous, and the odds are stacked against them. But at a time when stakes couldn't be higher, momentum is building and if successful, the tantalising possibility of an end to a dangerous legacy of dependence looms. Can it be done? And if so, what needs to change to make it happen? We ask these questions and more.

News Feature: The radical plan for vaccine equity

This project was supported by the Pulitzer Center.

Hosted on Acast. See acast.com/privacy for more information.